Table of contents
Trial overview
The available clinical trial data for Vemircopan includes one study, NCT05097989, which was a completed Phase 2 interventional trial.[1] The study tested ALXN2050 and compared it with placebo tablets in people with kidney disease.[1]
Conditions studied
This trial studied lupus nephritis and IgA nephropathy, which are both kidney diseases.[1] Lupus nephritis means kidney inflammation linked to lupus, while IgA nephropathy is a disease where IgA builds up in the kidneys and can lead to damage.[1]
The title of the study also described lupus nephritis as proliferative, which means a more active or severe form of the disease.[1]
Who could participate
The study enrolled participants with proliferative lupus nephritis or IgA nephropathy.[1] The source data do not provide extra details about age limits, sex, kidney function limits, or other entry rules.[1]
Study design and phase
This was a Phase 2 study, which is a mid-stage trial that usually checks whether a treatment may work and continues to monitor safety.[1] It was an interventional study, meaning researchers gave a study treatment and compared it with a control treatment.[1]
The study used ALXN2050 tablets and placebo tablets, so participants were compared against a treatment that looked the same but did not contain the active study drug.[1]
Outcomes measured
The main outcome was the percentage change in proteinuria.[1] Proteinuria means too much protein in the urine, which can be a sign that the kidneys are not filtering blood normally.[1]
The brief summary says the trial aimed to evaluate the efficacy of ALXN2050 to reduce proteinuria in participants with lupus nephritis or IgA nephropathy.[1] In simple terms, the study asked whether the treatment could lower the amount of protein leaking into the urine.[1]
